[Rational imaging in locally advanced prostate cancer].
Prostate cancer is one of the principal medical problems facing the male population in developed countries with an increasing need for sophisticated imaging techniques and risk-adapted treatment options. This article presents an overview of the current imaging procedures in the diagnosis of locally advanced prostate cancer. Apart from conventional gray-scale transrectal ultrasound (TRUS) as the most frequently used primary imaging modality we describe computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET). CT and MRI not only allow assessment of prostate anatomy but also a specific evaluation of the pelvic region. Color-coded and contrast-enhanced ultrasound, real-time elastography, dynamic contrast enhancement in MR imaging, diffusion imaging, and MR spectroscopy may lead to a clinically relevant improvement in the diagnosis of prostate cancer. While bone scintigraphy with (99m)Tc-bisphosphonates is still the method of choice in the evaluation of bone metastasis, whole-body MRI and PET using (18)F-NaF, (18)F-FDG, (11)C-choline, (11)C-acetate, and (18)F-choline as tracers achieve higher sensitivities.
Beissert
M
M
Institut für Röntgendiagnostik, Julius-Maximilians-Universität, Oberdürrbacher Strasse 6, 97080, Würzburg, Deutschland. beissert@roentgen.uni-wuerzburg.de
Lorenz
R
R
Gerharz
E W
EW
D001859:Bone Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000556:secondary; D001842:Bone and Bones / Q000473:pathology; D003952:Diagnostic Imaging; D006801:Humans; D007089:Image Enhancement; D007091:Image Processing, Computer-Assisted; D008297:Male; D009367:Neoplasm Staging; D011467:Prostate / Q000473:pathology; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000473:pathology; D012680:Sensitivity and Specificity; D013125:Spinal Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000556:secondary; D013131:Spine / Q000473:pathology
Cancer. 1999 Apr 1;85(7):1577-85
10193949
Eur J Nucl Med. 2001 Nov;28(11):1707-23
11702115
J Magn Reson Imaging. 2006 Feb;23(2):130-4
16374882
Nuklearmedizin. 2007;46(5):161-8; quiz N47-8
17938748
J Nucl Med. 1998 Jun;39(6):990-5
9627331
Radiology. 1972 Mar;102(3):701-4
5060184
J Nucl Med. 2006 Feb;47(2):287-97
16455635
Eur J Nucl Med Mol Imaging. 2008 May;35(5):976-83
18188560
J Nucl Med. 1962 Jul;3:332-4
13869926
Br J Radiol. 2005;78 Spec No 2:S103-11
16306632
Invest Radiol. 2006 Feb;41(2):185-8
16428991
J Med Imaging Radiat Oncol. 2008 Feb;52(1):24-8
18373822
Nuklearmedizin. 2003 Feb;42(1):25-30
12601451
Ultrasound Med Biol. 2008 Jul;34(7):1025-32
18255215
J Nucl Med. 2006 Jul;47(7):1102-6
16818944
J Comput Assist Tomogr. 2008 Mar-Apr;32(2):163-72
18379296
Eur Radiol. 2008 Apr;18(4):707-15
17938936
Rofo. 2005 Jun;177(6):788-95
15902626
Br J Urol. 1994 Jan;73(1):65-9
8298901
Curr Opin Urol. 2007 Jan;17(1):39-47
17143110
Eur J Nucl Med Mol Imaging. 2008 Jun;35(6):1065-73
18200444
Eur Urol. 2008 Dec;54(6):1354-62
18374470
Acta Radiol. 2008 Feb;49(1):107-20
18210320
J Urol. 1994 Nov;152(5 Pt 1):1520-5
7523710
J Urol. 1997 Mar;157(3):902-6
9072596
Anticancer Res. 2007 Nov-Dec;27(6C):4315-20
18214038
BJU Int. 2003 Jul;92(1):28-31
12823378
Rofo. 2008 Aug;180(8):746-52
18512192
Acta Radiol. 1990 Nov;31(6):597-600
2278785
Cancer Res. 2001 May 1;61(9):3599-603
11325827
J Nucl Med. 2002 Feb;43(2):181-6
11850482
Clin Radiol. 2008 Apr;63(4):387-95
18325358
Eur Urol. 2002 Jul;42(1):18-23
12121724
Eur J Nucl Med Mol Imaging. 2008 Jan;35(1):18-23
17891394
Urol Clin North Am. 2006 Aug;33(3):329-37
16829268
Eur J Nucl Med Mol Imaging. 2008 Feb;35(2):253-63
17926036
Eur Radiol. 2008 Jun;18(6):1281-91
18270715
Int J Urol. 2008 Jan;15(1):68-75; discussion 75
18184177